Tyrosine kinase inhibitors: Potential for the treatment of primary brain tumours

CNS Drugs

Volumn 12, Issue 6, 1999, Pages 421-430

  DeMattia, Joseph A ^a   Zhang, Wei ^a   Couldwell, William T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALPHA (3,4 DIMETHOXYBENZYLIDENE) 2 PYRIDYLACETONITRILE; EPIDERMAL GROWTH FACTOR RECEPTOR; LEFLUNOMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TYROSINE KINASE RECEPTOR; TYRPHOSTIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BRAIN TUMOR; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; GLIOBLASTOMA; GLIOMA; HUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW;

EID: 0033389033     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912060-00001     Document Type: Review

References (91)

1. 1. American Cancer Society. Cancer facts & figures. Atlanta (GA): American Cancer Society, 1997
2. 2. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. 2nd ed. Berlin: Springer-Verlag, 1993
3. 3. Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985; 35: 219-26
4. 4. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1998; 6: 338-43
5. 5. Albert FK, Forsting M, Sartor K, et al. Early post-operative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994; 34: 45-60
6. 6. Shapiro WR. Treatment of neuroectodermal brain tumors. Ann Neurol 1982; 12: 231-7
7. 7. Kornblith PL. The role of cytotoxic chemotherapy in the treatment of malignant brain tumors. Surg Neurol 1995; 44: 551-2
8. 8. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 1978; 49: 333-43
9. 9. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323-9
10. 10. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1725-31
11. 11. Loeffler JS, Shrieve DC, Alexander III E. Radiosurgery for glioblastoma multiforme: the importance of selection criteria. Int J Radiat Oncol Biol Phys 1994; 30: 731-3
12. 12. Gutin PH, Leibel SA, Wara WM, et al. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg 1987; 67: 864-73
13. 13. Curran Jr WJ, Scott CB, Weinstein AS, et al. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 1993; 11 (5): 857-62
14. 14. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983; 67: 121-32
15. 15. Brem H, Piantadosi S, Burger PC, et al. Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Polymer-Brain Tumor Treatment Group. Lancet 1995; 345: 1008-12
16. 16. Mahaley MS. Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy. J Neurooncol 1991; 11: 85-147
17. 17. Daumas-Duport C, Scheithauer B, O'Fallon J, et al. Grading of astrocytomas: a simple and reproducible method. Cancer 1988; 62: 2152-65
18. 18. Kelly KA, Kirkwood JM, Kapp DS. Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev 1984; 11: 1-26
19. 19. Choucair AK, Levin VA, Gutin PH, et al. Development of multiple lesions during radiation therapy and chemotherapy. J Neurosurg 1986; 65: 654-8
20. 20. Wilks AF, Kurban RR, Hovens CM, et al. The applications of the polymerase chain reaction to cloning members of the protein tyrosine kinase family. Gene 1989; 85: 67-74
21. 21. Morrison RS, Yamaguchi F, Bruner JM, et al. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 1994; 54: 2794-9
22. 22. Toyota M, Hinoda Y, Itoh F, et al. Complementary DNA cloning and characterization of truncated form of c-kit in human colon carcinoma cells. Cancer Res 1994; 54: 272-5
23. 23. Kikuchi K, Ueda M, Ikeda T, et al. Abnormalities and clinical characteristics of growth factors and receptor systems in breast cancer. Jpn J Cancer Chemoth 1994; 21 (2): 168-71
24. 24. Diez M, Maestro ML, Torres A, et al. Epidermal growth factor receptor in non-small cell cancer of the lung. Arch Bronconeumol 1994; 30 (6): 282-6
25. 25. Rong S, Jeffers M, Resau JH. Met expression and sarcoma tumorgenicity. Cancer Res 1993; 53: 5355-60
26. 26. DiRenzo MF, Olivero M, Prat M, et al. Overexpression of the Met/HGI receptor in normal and neoplastic human tissues. Oncogene 1991; 6: 1997-2003
27. 27. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-12
28. 28. Schlessinger J, Ullrich A. Growth factor signalling by receptor tyrosine kinases. Neuron 1992; 9: 383-91
29. 29. Bolen JB. Non-receptor tyrosine protein kinases. Oncogene 1993; 8: 2025-31
30. 30. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241: 42-52
31. 31. Schlegel J, Stumm G, Brandle K, et al. Amplication and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol 1994; 22: 201-7
32. 32. Bigner SH, Vogelstein B. Cytogenetics and molecular genetics of malignant gliomas and medulloblastomas. Brain Pathol 1990; 1: 12-8
33. 33. Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994; 9 (8): 2313-20
34. 34. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc Natl Acad Sci U S A 1992; 89: 4309-13
35. 35. Schlegel J, Merdes A, Stumm G, et al. Amplification of the epidermal-growth factor-receptor gene correlates with different growth behavior in human glioblastoma. Int J Cancer 1994; 56 (1): 72-7
36. 36. Hurtt MR, Moussy J, Donovan-Peluso M, et al. Amplification of epidermal growth factor receptor in gliomas: histopathology and prognosis. J Neuropath Exp Neurol 1992; 51 (1): 84-90
37. 37. Bernstein JJ, Anagnostopoulos AV, Hattwick EA, et al. Human-specific c-neu proto-oncogene protein overexpression in human malignant astrocytomas before and after xenografting. J Neurosurg 1993; 78: 240-51
38. 38. Gilbertson RJ, Perry RH, Kelly PJ, et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997; 57: 3272-80
39. 39. Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993; 4: 19-26
40. 40. Kraus MH, Issing W, Miki T, et al. Isolation and characterization of ErbB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A 1989; 86: 9193-7
41. 41. Plowman GD, Culouscou JM, Whitney GS, et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A 1993; 90: 1746-50
42. 42. Data on file, Penar PL, 1998
43. 43. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem 1994; 69: 32023-6
44. 44. Antoniades HN, Scher CD, Stiles CD. Purification of human platelet-derived growth factor. Proc Natl Acad Sci U S A 1979; 76: 1809-12
45. 45. Eva A, Robbins KC, Andersen PR, et al. Cellular genes analogous to retroviral ons genes are transcribed in human cancer. Nature 1982; 295: 116-9
46. 46. Nister M, Libermann TA, Betsholtz C, et al. Expression of mRNAs for platelet-derived growth factor and transforming growth factor-α and their receptors in human malignant glioma cell lines. Cancer Res 1988; 48: 3910-8
47. 47. Nister M, Claesson-Welsh L, Eriksson A, et al. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1992; 266: 16755-63
48. 48. Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52: 3213-9
49. 49. Doolittle RF, Hunkapiller MW, Hood LE, et al. Simian sarcoma oncogene, v-sis, is derived from the gene (or genes) encoding platelet-derived growth factor. Science 1983; 221: 275-7
50. 50. Deinhardt F. The biology of primate retrovirus. In: Klein G, editor. Viral oncology. New York (NY): Raven Press, 1980: 359-98
51. 51. Ferrara N, Houck K, Jakeman L, et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32
52. 52. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and development expression suggests flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-46
53. 53. Berkman RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993; 91: 153-9
54. 54. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995; 55: 1189-93
55. 55. Plate KH, Breier G, Millauer B, et al. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994; 59: 520-9
56. 56. Murphy PA. Phytoestrogen content of processed soybean products. Food Technol 1982; 36: 62-4
57. 57. Peterson G. Evaluation of the biochemical targets of genistein in tumor cells. J Nutr 1995; 125: 7845-95
58. 58. Levitzki A. Tyrphostins: potential antiproliferative agents and novel molecular tools. Biochem Pharmacol 1990; 40: 913-8
59. 59. Paschal A, Weernink O, Verheul E, et al. Inhibitors of protein tyrosine phosphorylation reduce the proliferation of two human glioma cell lines. Neurosurgery 1996; 38: 108-13
60. 60. Shawver LK, Schwartz DP, Mann E, et al. Inhibition of platelet-derived growth factor mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997; 3: 1167-77
61. 61. Vassbotn FS, Ostman A, Langeland N, et al. Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. J Cell Physiol 1994; 158: 381-9
62. 62. Strawn LM, Mann E, Elliger SS, et al. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-β receptor. J Biol Chem 1994; 269: 21215-22
63. 63. Shamah SM, Stiles CD, Guha A. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 1993; 13: 7203-12
64. 64. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841-4
65. 65. Millauer B, Shawver CK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-9
66. ∧ glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996; 56: 393-401
67. 67. Stratmann A, Machein MR, Plate KH. Anti-angiogenic gene therapy of malignant glioma. Acta Neurochir 1997; 68: 105-10
68. 68. Penar PL, Khoshyomn S, Bhushan A, et al. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 1997; 40: 141-51
69. 69. Khoshyomn S, Penar PL, Rossi J, et al. Inhibition of phospholipase C-gamma1 activation blocks glioma cell motility and invasion of fetal rat brain aggregates. Neurosurgery 1999; 44: 568-77
70. 70. Couldwell WT, Weiss MH, Weiner LP, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high dose tamoxifen. Neurosurgery 1993; 32: 485-90
71. 71. Mastronardi L, Puzzilli F, Couldwell WT, et al. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neurooncol 1998; 38: 59-68
72. 72. Malkin MG, Rosen L. Lopez AM, et al. Phase 2 study of SU101, a PDGF-R signal transduction inhibitor, in recurrent malignant glioma [abstract]. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16-19; Los Angeles (CA); 17: 390
73. 73. O'Brian CA, Liskamp RM, Solomon DH, et al. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985; 45: 2452-65
74. 74. Couldwell WT, Hinton DR, Surnock AA, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2: 619-22
75. 75. Vertosick Jr FT, Selker RG, Pollack IF, et al. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of 'failed' patients. Neurosurgery 1992; 30: 897-902
76. 76. Baltuch GH, Shenouda G, Langleben A, et al. High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression. Can J Neurol Sci 1993; 20: 168-70
77. 77. Malkin MG, Rosen L, Lopez AM, et al. Phase 2 study of SU101. a PDGF-R signal transduction inhibitor, in recurrent malignant glioma [abstract]. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16-19; Los Angeles (CA); 17: 390
78. 78. Pollack IF, Kawecki S, Lazo JS. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-101, a selective protein kinase C inhibitor. J Neurosurg 1996; 84: 1024-32
79. 79. Anker L, Gopalakrishna R, Law RE, et al. Hypericin: an anti-tumor agent. Drugs Fut 1995; 20: 511-7
80. 80. Zhang W, Hinton DR, Surnock AA, et al. Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen and hypericin: corroborating clinical response in vitro. Neurosurgery 1996; 38: 587-91
81. 81. Hamilton HB, Hinton DR, Law RE, et al. Inhibition of growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. J Neurosurg 1996; 85: 329-34
82. 82. Daniel C. Further communications on the photodynamic substance hypericin. Hippokrates 1949, 19: 526-30
83. 83. Takahashi I, Nakanishi S, Kobayashi E, et al. Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity. J Antibiot 1989, 42: 153-7
84. 84. Couldwell WT, Gopalakrishna R, Hinton DR, et al. Hypericin: a potential antiglioma therapy. Neurosurgery 1994; 35: 705-10
85. 85. Couldwell WT, Hinton DR, He S, et al. Protein kinase C inhibitors induce apoptosis in human malignant glioma lines. FEBS Lett 1994; 345: 43-6
86. 86. Zhang W, Law RE, Hinton DR, et al. Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C. Cancer Lett 1995; 96: 31-5
87. 87. Zhang W, Law RE, Hinton DR, et al. Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Lett 1997; 120: 31-8
88. 88. Okpanyi SN, Weischer ML. Animal experiments on the psychotropic action of a hypericum extract. Arzneimittel Forschung 1987; 37: 10-30
89. 89. Suzuki O, Katsumata Y, Oya M, et al. Inhibition of monamine oxidase by hypericin. Planta Med 1984; 50: 272-4
90. 90. Liebes L, Mazur Y, Freeman D, et al. A method for the quantitation of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem 1991; 195: 77-85
91. 91. Zhang W, Law RE, Hinton DR, et al. Radiosensitization of malignant human glioma cells by hypericin in vitro. Clin Cancer Res 1996; 2: 843-6